Corporate Actions

Entry into a Material Definitive Agreement. On February 20, 2026, The Cannabist Company Holdings Inc. (“The Cannabist Company” or “the Company”) announced that the ad hoc group of noteholders of the Company’s 9.25% Senior Secured Notes due December 31, 2028 and the 9.00% Senior Secured Convertible Notes due December 31, 2028 (collectively, the “Notes”), which are parties to the previously announced forbearance agreement with the Company, have agreed to a further extension and to forbear from exercising any of their rights and remedies under the amended and restated indenture, as supplemented, governing the Notes and applicable law, until February 27, 2026. Forward-Looking Statements This Current Report contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 and corresponding Canadian sec

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Transfer of Stock Exchange Listing to Nasdaq On February 23, 2026, Culp, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, notified the New York Stock Exchange (“NYSE”) of its intention to voluntarily withdraw the listing of the Company’s common stock, par value $0.05 per share (the “Common Stock”), from the NYSE and transfer the listing to The Nasdaq Stock Market LLC (“Nasdaq”). The Company expects that listing and trading of its Common Stock on the NYSE will end at market close on March 5, 2026, and that trading will begin on Nasdaq at market open on March 6, 2026. The Common Stock has been approved for listing on Nasdaq, where it will continue to trade under the stock symbol “CULP.” Item 7.01 Regulation FD Disclosure. The Company issued the news relea

Regulation FD Disclosure. On February 23, 2026, the Company issued a press release, a copy of which is furnished herewith as Exhibit 99.1. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section. Furthermore, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits

Entry into a Material Definitive Agreement Amendment to Revolving Loan Agreement On February 23, 2026, CNL Strategic Capital B, Inc. (“Borrower”), a wholly-owned subsidiary of CNL Strategic Capital, LLC ( the “Company”) and Valley National Bank, a Tennessee banking corporation, (referred to as “Valley National Bank”) entered into an Amendment (“Amendment”) to the Loan and Security Agreement (the “Loan Agreement”) previously entered into by such parties for a revolving line of credit (the “Line of Credit”). Under the Amendment, unless further extended, the Line of Credit has a new maturity date of May 15, 2026. The foregoing description of the Amendment in this Item 1.01 does not purport to be complete in scope and is qualified in its entirety by the full text of such agreement included as Exhibit 10.1 to this filing and incorporated by reference herein. Item 2.03 Creation of a Direct Fi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 19, 2026, Douglas C. Taylor, the Lead Director of the Board of Directors (the “Board”) of Cleveland-Cliffs Inc. (the “Company”), submitted his resignation as a member of the Board, conditional on acceptance by the Board. Mr. Taylor’s decision to resign was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Rather, pursuant to the Company’s Corporate Governance Guidelines, a director is required to tender his or her resignation when, among other things, the director experiences a change in primary occupation, position or primary business affiliation. On February 22, 2026, based on the recommendation of the Governance and Nominating Committee of the Board, the

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026, Kristie L. Colvin notified CenterPoint Energy, Inc. (the “Company”) of her intent to retire from the Company on June 1, 2026. She will retire from her position as Senior Vice President and Chief Accounting Officer of the Company and its affiliated subsidiaries on March 2, 2026, and will transition to an advisory role to support the transition to her successor until her retirement from the Company. Ms. Colvin’s decision to retire is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies and practices, including any matters concerning the Company’s controls or any financial or accounting-related matters or disclosures. In connection with Ms. Colvin’s retirement, on

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026, Kristie L. Colvin notified CenterPoint Energy, Inc. (the “Company”) of her intent to retire from the Company on June 1, 2026. She will retire from her position as Senior Vice President and Chief Accounting Officer of the Company and its affiliated subsidiaries on March 2, 2026, and will transition to an advisory role to support the transition to her successor until her retirement from the Company. Ms. Colvin’s decision to retire is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies and practices, including any matters concerning the Company’s controls or any financial or accounting-related matters or disclosures. In connection with Ms. Colvin’s retirement, on

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026, Kristie L. Colvin notified CenterPoint Energy, Inc. (the “Company”) of her intent to retire from the Company on June 1, 2026. She will retire from her position as Senior Vice President and Chief Accounting Officer of the Company and its affiliated subsidiaries on March 2, 2026, and will transition to an advisory role to support the transition to her successor until her retirement from the Company. Ms. Colvin’s decision to retire is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies and practices, including any matters concerning the Company’s controls or any financial or accounting-related matters or disclosures. In connection with Ms. Colvin’s retirement, on

REGULATION FD DISCLOSURE Members of Centene Corporation's (the Company's) senior management team will meet with investors the week of February 23, 2026. Consistent with the Company's guidance previously provided on February 6, 2026, the senior management team plans to reaffirm the Company's 2026 full year GAAP diluted earnings per share (EPS) guidance of greater than $1.98 and its full year adjusted diluted EPS guidance of greater than $3.00. Non-GAAP Financial Presentation The Company is providing certain non-GAAP financial measures in this Form 8-K as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally in evaluating the Company's performance and for pl

Unregistered Sales of Equity Securities. As previously reported, on September 4, 2025, Cadence Design Systems, Inc., a Delaware corporation (“Cadence”), entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Hexagon Smart Solutions AB, a Swedish private limited liability company (“Seller”), to acquire Seller’s design and engineering business (the “Acquisition”). In connection with the consummation of the Acquisition on February 23, 2026, Cadence issued 3,224,473 shares of Cadence’s common stock, par value $0.01 per share (the “Stock Consideration”), to Seller as partial consideration for the Acquisition. Cadence issued the Stock Consideration in reliance upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation S promulgated under the Securities Act. SIGNATURES Pursuant to the r

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on August 21, 2025, BullFrog AI Holdings, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing (the “Stockholders’ Equity Requirement”). The Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement (the “Plan”) to Nasdaq on September 30, 2025. In response to the Company’s Plan, on October 7, 2025, the Company received a letter (the “Extension Letter”) from Nasdaq informing the Company that, based on the Plan, Nasdaq had granted the Company’s request for an extension until February

Results of Operations and Financial Condition. On February 23, 2026, Brighthouse Financial, Inc. (“Brighthouse Financial” or the “Company”) issued (i) a news release announcing its results for the quarter and full year ended December 31, 2025, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, and (ii) a Financial Supplement for the quarter ended December 31, 2025, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 and Exhibits 99.1 and 99.2 listed in Item 9.01 of this Current Report on Form 8-K shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by refe

Entry Into a Material Definitive Agreement. 2026-FL3 CLO Transaction Overview On February 17, 2026 (the “CLO Closing Date”), BrightSpire Capital, Inc. (the “Company”) entered into a collateralized loan obligation (the “CLO”) through its subsidiary real estate investment trust, BrightSpire Capital Mortgage Sub-REIT, LLC (“Sub-REIT”), and two wholly-owned subsidiaries of Sub-REIT, BRSP 2026-FL3 Ltd., a newly formed exempted company incorporated with limited liability under the laws of the Cayman Islands, as issuer (the “Issuer”), and BRSP 2026-FL3, LLC, a Delaware limited liability company, as co-issuer (the “Co-Issuer” and together with the Issuer, the “CLO Issuers”). On the CLO Closing Date, the CLO-Issuers issued six classes of notes, the Class A Notes, the Class A-S Notes, the Class B Notes, the Class C Notes, the Class D Notes and the Class E Notes (the “Offered Notes”), and the Issu

REGULATION FD DISCLOSURE. On February 23, 2026, Braemar Hotels & Resorts Inc. (the “Company”) issued a press release announcing that its Board of Directors declared February 2026 dividends for its 5.5% Series B Cumulative Convertible Preferred Stock, 8.25% Series D Cumulative Preferred Stock, Series E Redeemable Preferred Stock and Series M Redeemable Preferred Stock. As of January 31, 2026, there were 11,778,269 shares of the Company's Series E Redeemable Preferred Stock and 1,388,674 shares of the Company's Series M Redeemable Preferred Stock issued and outstanding. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K and Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing

Other Events. On February 15, 2026, Borealis Foods Inc. (the “Company”), together with certain of its subsidiaries, entered into a commitment letter with a third-party lender providing for a proposed senior secured credit facility (the “Proposed Credit Facility”). The Proposed Credit Facility is expected to consist of a senior secured term loan and a senior secured revolving credit facility, subject to the negotiation and execution of definitive credit documentation and the satisfaction of customary closing conditions. The Company intends to use the proceeds of the Proposed Credit Facility, if consummated, to refinance its existing credit facility with Frontwell Capital Partners Inc. and expects that the Proposed Credit Facility would provide additional liquidity and financing flexibility to support its ongoing operations and growth initiatives. The commitment letter contains customary

Regulation FD Disclosure. On February 23, 2026, Fulton Financial Corporation, a Pennsylvania corporation (“Fulton”) and Blue Foundry Bancorp, a Delaware corporation (“Blue Foundry”), issued a joint press release announcing that all required regulatory approvals have been obtained for the previously announced all-stock transaction in which Blue Foundry will merge with and into Fulton (the “Merger”), with Fulton surviving the Merger. Following the Merger, around the time of systems conversion, Blue Foundry Bank, a New Jersey-chartered stock savings bank and wholly owned subsidiary of Blue Foundry, will merge with and into Fulton Bank, N.A. (“Fulton Bank”), a national banking association and wholly owned subsidiary of Fulton (the “Bank Merger” and, together with the Merger, the “Transaction”), with Fulton Bank continuing as the surviving bank in the Bank Merger. A copy of the press release

Entry into a Material Definitive Agreement. On February 17, 2026, Better Home & Finance Holding Company (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with Framework Ventures IV L.P. (“Purchaser”). Pursuant to the SPA, the Company issued and sold a warrant (the “Warrant”) to purchase up to an aggregate of 211,312 shares (the “Warrant Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), upon the terms and subject to the limitations on exercise and conditions set forth in the Warrant. The purchase price of the Warrant was $0.01 (the “Purchase Price”). The Warrant is exercisable upon the occurrence of two separate exercisable events. The first exercisable event (“Exercisable Event A”) shall occur when Purchaser’s (together with its Attribution Parties (as defined in the Warrant)) beneficial ownership exceeds 4.99% of th

Results of Operations and Financial Condition. On February 23, 2026, the Company issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the press release and supplemental earnings presentation is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference. This information is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1

Results of Operations and Financial Condition. On February 23, 2026, we issued a press release announcing our financial results for the fourth quarter ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1, and the information contained in Exhibit 99.1 is incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Earnings Release dated February

Changes in Registrant’s Certifying Accountant. On February 20, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of BV Financial, Inc. (the “Company”) approved the dismissal of Forvis Mazars, LLP (“Forvis Mazars”) as the Company's independent registered public accounting firm effective upon completion by Forvis Mazars of its audit of the Company's consolidated financial statements for the fiscal year ended December 31, 2025 and the filing of the Company's 2025 Annual Report on Form 10-K (the "Effective Date"). On February 20, 2026, the Audit Committee notified Forvis Mazars of the dismissal as of the Effective Date. Concurrently, the Audit Committee approved the engagement of Crowe LLP (“Crowe”) as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2026, effective as of the Effect Date. The Company’s formal e

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in BRC Inc.’s (the “Company”) Current Report on Form 8-K filed on September 17, 2025, as amended by Amendment No. 1 to the Current Report on Form 8-K/A filed on September 19, 2025 (the “Original 8-K”), on September 15, 2025, the Board of Directors (the “Board”) of the Company increased the size of the Board from nine to ten members and appointed Melvin Landis to fill the vacancy created by such increase in the size of the Board. At the time the Original Form 8-K was filed, the Board had not yet made a determination regarding Board committee assignments for Mr. Landis. The Company is filing this Amendment No. 2 to the Original 8-K solely to report that, on February 17, 2026, the Board appointed Mr. Landis to serve on t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in BRC Inc.’s (the “Company”) Current Report on Form 8-K filed on April 15, 2025 (the “Original 8-K”), on April 11, 2025, the Board of Directors (the “Board”) of the Company increased the size of the Board from seven to nine members and appointed Sean Moriarty to fill one of the vacancies created by such increase in the size of the Board. At the time the Original Form 8-K was filed, the Board had not yet made a determination regarding Board committee assignments for Mr. Moriarty. The Company is filing this Amendment No. 1 to the Original 8-K solely to report that, on February 17, 2026, the Board appointed Mr. Moriarty to serve on the Board’s Audit Committee and as a member and chair of the Board’s Nominating & Corpora

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026 the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director of the Company, to hold office until the next annual meeting of stockholders, in each case, effective February 18, 2026. The Board further appointed Ms. Smith to serve as a member of the Audit Committee and the Nominating and Governance Committee of the Board, and Mr. Weber to serve as a member of the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee of

Regulation FD Disclosure. On February 23, 2026, Bitmine Immersion Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) providing an update on the Company’s operations. A copy of the Press Release is attached as Exhibit 99.1 and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated February 23, 2026. 1

Results of Operations and Financial Condition. On February 23, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2025. The Company’s press release issued on February 23, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 19, 2026, the Corporate Governance and Compensation Committee of the Board of Directors of BellRing Brands, Inc. (the “Company”) approved a special grant of restricted stock units (“RSUs”) to certain of the Company’s named executive officers in the following amounts and values: Name and Principal Position Number of RSUs Grant Date Fair Value of RSUs Paul A. Rode Chief Financial Officer 29,043 $551,236 Douglas J. Cornille Chief Growth Officer 27,209 $516,427 Craig L. Rosenthal Chief Legal Officer, Chief Compliance Officer and Secretary 26,349 $500,104 Robin Singh Chief Supply Chain Officer - Premier Nutrition 23,877 $453,185 The RSUs are intended to promote retention during the previously disclosed CEO transition period and will v

Results of Operations and Financial Condition On February 23, 2026, Bed Bath & Beyond, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the three and twelve months ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. In connection with the release of financial results, the Company posted an updated presentation in the "Events & Presentation" portion of its investor relations website at https://investors.beyond.com. The information in this Current Report on Form 8-K and in Exhibit 99.1 is furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as may expressly be set fo

Entry into a Material Definitive Agreement Disclosure is required regarding entry into or amendment of any definitive agreement that is material to the securitization, even if depositor is not a party.   Examples: servicing agreement, custodial agreement. Note: disclosure not required as to definitive agreements that are fully disclosed in the prospectus ● Trustee/Certificate Administrator/Master Servicer/Depositor/Special Servicer as to the Trust (only as to the agreements such entity is a party to or entered into on behalf of the Trust) Item 1.02- Termination of a Material Definitive Agreement Disclosure is required regarding termination of  any definitive agreement that is material to the securitization (other than expiration in accordance with its terms), even if depositor is not a party.  ● Trustee/Certificate Administrator/Master Servicer/Depositor/Special Servicer as to the Trus

Results of Operations and Financial Condition. On February 23, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2025 and provided an update on the Company’s operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expre

of this Current Report is incorporated by reference into this Item 3.02. The Company issued the Warrant pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) available under Section 4(a)(2) of the Securities Act. Pursuant to the terms of the Warrant, the Company intends to file a registration statement relating to the resale of the Company’s Common Stock underlying the Warrant, subject to the registration rights provisions of the Warrant. Item 8.01 Other Events. On February 23, 2026, the Company issued a press release titled “Atara Biotherapeutics Provides a Business Update”. A copy of the press release is filed as Exhibit 99.1 and incorporated by reference into this Item 8.01. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1 Form of Warrant 10.1 Amendment No. 1 to the Purchase a

Material Modification to Rights of Security Holders. On February 19, 2026, the Company obtained written consent from the holder of its Series E Preferred Stock, representing approximately 67.7% of the total voting power, to approve a strategic capital realignment. This realignment includes an increase in authorized common shares and a pending 1-for-100 reverse stock split. The increase in authorized shares provides the Company with additional liquidity to meet contractual obligations but may result in significant future dilution for existing common shareholders. The reverse stock split has been submitted to FINRA for processing and remains pending review. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 19, 2026, the Board of Directors and a majority of the Company's voting power approved a Certificate of Amendment to the Articles of Incorp

Regulation FD Disclosure. On February 23, 2026, Armata Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted the Qualified Infectious Disease Product designation to AP-SA02, the Company’s intravenously-administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in

Results of Operations and Financial Condition. On February 23, 2026, the Company announced its financial results for the three months and year ended December 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this current report on Form 8-K. The information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated February 23, 2026 104 Cover

Regulation FD Disclosure. On February 23, 2026, certain of Antero Midstream Corporation’s wholly-owned subsidiaries completed the previously announced sale of substantially all of their Utica Shale midstream assets to an affiliate of Infinity Natural Resources, Inc. and Northern Oil and Gas, Inc. (“NOG”) for aggregate cash consideration of $400 million, subject to customary post-closing adjustments, adjustments for the effective date of the transaction and other items, as contemplated by the Purchase and Sale Agreement, dated December 5, 2025, among Antero Midstream LLC, Antero Water LLC, Antero Treatment LLC, Infinity Natural Resources, LLC and NOG, as amended to date. The information furnished in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall su

Entry into a Material Definitive Agreement On February 17, 2026, Angel Studios, Inc., a Delaware corporation (the “Company”), and certain of the Company’s subsidiaries entered into a Ratification and First Amendment to Loan and Security Agreement, effective as of September 9, 2025 (the “First Credit Facility Amendment”), which amended the Loan and Security Agreement (the “Credit Facility”), dated as of September 8, 2025, by and among Angel Studios Legacy, Inc. (f/k/a Angel Studios, Inc.), a Delaware corporation (the “Original Borrower”), and certain of the Original Borrower’s subsidiaries, certain lenders thereunder, and Trinity Capital Inc., a Maryland corporation, as agent for the lenders (“Administrative Agent”). The First Credit Facility Amendment ratifies certain transactions and amends the Credit Facility in connection with the Company’s consummation of a business combination tran